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Abstract 
The interaction of steroid hormones (testosterone and progesterone) with human serum albumin in phosphate buffer at pH 7.5 and at 25 
°C have been studied using a fluorescence spectrophotometer. The results showed that fluorescence emission spectra were quenched with the 
increase of steroid molar ratios in fixed amount of HSA. The result indicated that progesterone and testosterone hormones have an ability to 
quench the intrinsic fluorescence of HSA through a static quenching procedure. Two mathematical models Stern–Volmer and Scatchard for 
analysis of fluorescence spectra were used. Progesterone binding to HSA was increased by a factor of  2.6 greater than that detected for the 
interaction of testosterone with HSA.  
The values of Stern-Volmer constants were determined to be (2.0  104 L mol-1) for progesterone–HSA complex and (7.7  103  L mol-1) 
for testosterone–HSA complex, Respectively. Whereas, the Scatchard constants were (2.1  104 L mol-1) and (7.9  103  L mol-1) for 
progesterone–HSA and  testosterone–HSA complexes, respectively.   
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INTRODUCTION  
 
Steroid hormones are the most familiar compounds to 
the general public, because of the use and abuse of them. it 
for diverse purposes, such as contraception and body 
building [1]. Steroid hormones have many physiological 
effects on human body, their disorder may cause many 
abnormalities in human body [2, 3]. Progesterone, as a 
steroid hormone, is synthesized from cholesterol [1], and is 
secreted naturally by the corpus luteum. It is a C-21 steroid 
hormone; its chemical structure is shown in Fig.(1 a and b) 
[2]. 
 
 
 
Testosterone, a “male’’ or masculinizing sex hormone, 
is a C-19 steroid Fig.(1 b) is secreted from the testis and the 
adrenal cortex in men and from the adrenal cortex and 
ovaries in women. It has important functions in stimulating 
and maintaining the secondary sex characteristics (such as 
beard growth), maintaining the genitals and their sperm-
producing capability, and stimulating the growth of bone 
and muscle [4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of steroid hormones (a): Progestrone and (b):  Testosterone)  
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Human serum albumin (HSA) Fig. 2 is a globular 
single polypeptide chain protein of a molecular mass of 
about 67 kDa and comprises 585 amino acid residues, It is 
the most abundant and highly soluble plasma protein in the 
blood circulatory system in mammals (approximately 60% 
of the total protein) [6, 7] the most abundant plasma 
protein, greatly augments the transport capacity of blood 
plasma where it is present at a high concentration (≈ 600 
μM). This property is exerted by reversible binding and 
delivering of a vast array of chemically diverse endo- and 
exogenous compounds [8, 9] seriously impacting their 
pharmacokinetic profile. HSA plays an important role in 
transporting metabolites and drugs through the vascular 
system and also in maintaining the pH and osmotic 
pressure of the plasma [11]. Its structure includes three 
homologous domains (I, II, and III) that assemble a heart 
shaped molecule (Fig. 2). Each domain is formed by two 
sub-domains (A and B) which possess common structural 
motifs by various forces such as salt bridges and 
hydrophobic interactions [12, 13]. According to the 
conventional view based on Sudlow’s classification, drug 
ligands of HSA are accommodated at two main [6, 8] 
Crystallographic studies performed on ligand-HSA adducts 
have revealed the molecular details of the binding [5−9] 
Site IIA is a large, preformed, flexible multichamber cavity 
within the core of subdomain IIA which binds bulky 
heterocyclic compounds with a negative, often delocalized 
charge near to the center of a mainly nonpolar molecular 
framework. However, the Sudlow classification cannot 
account for the HSA binding of all ligands. A third binding 
pocket within subdomain IB (site IB) has recently been 
identified as the primary binding site of some compounds 
such as bilirubin photoisomer [14], hemin [15,16]. 
Crystallographic studies have also showed that the large 
crevice of subdomain IB harbors secondary binding sites 
for some additional compounds. 
 
 
 
 
Figure 2. X-ray crystallographic to 2.5Å resolution of three 
dimensional Structure of HSA, with its subdomains [5]. The 
structure corresponds to the ‘‘Protein Data Bank’’.  
 
Carter and co-workers [17, 18] have claimed that 
subdomain IB (site IB) is the third major drug-binding 
region of HS. 
In this work, it is informative to study the  interaction 
between two selected steroid hormones (testosterone and 
progesterone) with human serum albumin using 
fluorescence quenching method, and tried to do a 
comparison between the binding behavior of both 
hormones with HSA. The results will be  interpreted on the 
basis of two mathematical models leading to estimate the 
binding parameters for both hormones with HSA.  
MATERIALS AND METHODS 
 
Human serum albumin (HSA) (fatty acid free) was 
purchased from Sigma Aldrich company, and the hormones 
testosterone ampoule was purchased from Alexandria Co. 
pharmaceutical chemical industries and progesterone 
ampoule from Marcyrl pharmaceutical industries, and their 
solutions were prepared as 5% ethanolic phosphate buffer 
solutions. The other substances are of reagent grade, and 
were used without further purifications. 
 
Preparation of Stock Solutions 
HSA solution was freshly prepared in phosphate buffer 
saline (20 mM, 0.1 M NaOH pH 7.5) and treated at final 
concentration of 1 µM with the previously prepared 
hormone solution testosterone or Progesterone. The studied 
hormone, was dissolved in phosphate buffer saline (5% 
ethanolic solution). 
The concentration of HSA was determined from 
absorbance measurements at 278 nm using a molar 
extinction coefficient of 35219 M-1cm-1. [19] 
Unless otherwise noted, all reagents used in this study 
were used as received without further purification. All 
solutions in this study were prepared with doubly distilled 
water.The phosphate buffer was 20 mM (containing 0.1 M 
NaCl) and its pH was adjusted to pH 7.5) 
 
Fluorescence Quenching Study  
All fluorescence spectra were recorded on an Perkin–
Elmer luminescence Spectrofluorimeter, (series no. 70412). 
A quartz cell of 1.00 cm width was used for the 
fluorescence measurements. Fluorescence spectra related to 
the titration of fixed volume of HSA of 1 µM concentration 
with concentrated stock ethanolic steroid solution (varied 
from 0.35 mM to 6.0 mM) were measured on the 
Spectrofluorimeter. 
The fluorescence intensity measured were corrected for 
background fluorescence of buffer and the steroids studied. 
All samples were measured after two minutes and all 
binding data reported here correspond to the average values 
obtained after two different titrations. The instrument was 
thermostatically controlled by a circulatory water  bath 
maintained at 25 °C.  
The fluorescence emission spectra in absence and 
presence of increasing concentration of the studied steroid 
were recorded at 25 °C in the wavelength range of 
250 – 500 nm with the excitation wavelength at 295 nm 
and the widths of both excitation and emission slits were 
fixed to 10  
 
Calculation of HSA Binding Constants 
The apparent binding constants for both steroids with 
HSA were obtained after collecting fluorescence quenching 
data using two mathematical models, equations 1 and 2. 
Details of the estimation of the association constants (Ka) 
using fluorescence quenching data have been described 
elsewhere.  Nonlinear regression analysis of the binding 
constant values measured at different steroid/HSA molar 
ratios was performed and analyzed by the Matlab software 
program (2008). 
 
Stern-Volmer
   )1(1][1 SV0 fq HHKFF    
Where: 
0
F and F are the fluorescence intensities in the 
absence and presence of the quencher, respectivety. Ksv is 
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the Stern-Volmer quenching constant. and [H]f is the free 
hormone concentration and can be expressed as: 
 
     btf HHH  ……………………… (2) 
 
Where: [H]t the total  hormone concentration and [H]b 
is the bound hormone concentration. 
Kq is the bimolecular quenching constant,   is the 
average lifetime of the biomolecule without quencher, and 
(H) is the quencher concentration 
 
Scatchard 
 
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f
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r
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Where: Ksc is the Scatchard association constant, n is 
the number of binding sites, and r is the number of mol of 
bound ligand per mol of protein,and can be calculated as: 
 
 
 
)4(..............
t
b
HSA
H
r   
Where:    [HSA]t is the total concentration of protein. 
 
RESULTS AND DISCUSSION 
 
Fluorescence quenching spectra 
Fluorescence spectroscopy is one of the most widely 
used spectroscopic technique to study the protein ligand 
binding and interaction [20, 21]. Fluorescence quenching of 
single tryptophan residue in HSA (Trp 214) was used to 
monitor the steroid/HSA interaction and to measure the 
binding affinity of the interaction quenching spectra of 
HSA at various molar ratios of progesterone is shown in 
Fig.(3). Obviously from the results, the fluorescence 
intensity of 
 
 
Fig. 3 Emission spectra of HSA in the absence and the presence of 
hormone (a): progesterone and (b): testosterone at various hormone 
concentrations, T = 298 K, λex = 295 nm, λem = 350 nm, pH = 7.50 
and the HSA concentration was 1.0 µM. The concentrations of 
hormone drug was varied from 0.35 to 6.0 mM in each case. 
It is obviously from the results, that the fluorescence 
intensity of HSA gradually quenched upon increasing the 
molar ratio of the studied hormone to HSA, indicating that 
progesterone and testosterone bind to HSA.  
It is seen that, the amount of fluorescence quenching 
caused by the steroid molecules was dependent on the 
steroid type and concentration being more effective in case 
of progesterone/HSA. Furthermore, a slight blue shift of the 
maximum emission wavelength was observed at higher 
steroid concentrations that it could be suggested that 
conformational changes induced by the interaction of 
steroid with HSA, lead to a further hiding of tryptophan 
residues from the polar solvent [23-25] that is the 
interaction of the studied steroid with HSA induced an 
alteration of the tertiary structure of HSA [22] being more 
effective in case of progestrone.  
The fluorescence emission spectra of a compound is 
quenched due to a variety of molecular interactions, one of 
which is the formation of a complex between the 
fluorophore and the quencher.  
Stern-Volmer quenching constant Ksv indicates the 
sensitivity of the fluorophore to a quencher. Figure (4 a and 
b) displays the Stern–Volmer plots of the quenching of 
HSA by the studied steroid molecules at 25 °C, in 
phosphate buffer solution at pH 7.5. 
 
 
 
 
Fig. 4. Stern-Volmer plots of fluorescence quenching of HSA by 
(a): progesterone and (b): testosterone. 
 
Table 1 lists the binding constants obtained by both 
models i.e Stern-Volmer and that of Scatchard  (KSV and 
KSc). It is evident that, progesterone was apparently bound 
more than twice as high as that for testosterone and this 
trend was in accordance (to some extent) with the same 
trend with that was obtained by [28] The differences in 
binding behaviors between progesterone and testosterone 
with HSA may be due to binding mode of interaction of 
different side chains in the two studied steroidal hormones 
and the selected binding region in HSA.  [29]  
 
Table 1. Association constants of progesterone and 
testosterone with HSA in phosphate buffer pH 7.5 and at 
25°C. 
Hormone Binding  constant (M-1) 
 Stern-Volmer Scatchard 
Progestrone 2.0  104 2.1  104 
Testosterone 7.7  103 7.9  103 
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The apparent binding constants (KSV and KSc) for the 
studied hormone that binds HSA can be obtained using 
Eqs. (1) and (3) Stern–Volmer and Scatchard, respectively 
[26,  [27].  
The fluorescence quenching data accompaining the 
interaction hormone/HSA in the present study were 
analyzed on the basis of two well known mathematical 
models, Stern–Volmer and Scatchard models, Eqs (1) and 
(2), respectively. The corresponding linear regression 
equations were analysed by using Matlab software. 
 
Figs. (5 a and b) shows the Scatchard plots for the 
interaction of hormone/HSA at 25 °C.     
 
 
 
 
Fig. 5. Scatchard plots of fluorescence quenching of HSA by (a): 
progesterone and (b): testosterone. 
 
CONCLUSION  
 
In this paper, we investigated the interaction between 
two steroid hormones (Progestrone and testosterone) by 
fluorescence spectroscopy. The experimental results 
indicate that both hormones can quench the intrinsic 
fluorescence of HSA. Our results clarified that 
progesterone was bound more effectively to HSA. The 
binding constants were calculated and analyzed according 
to two mathematical models (Stern-Volmer and Scatchard). 
This study is expected to provide important insights into 
the interaction of protein HSA with important drugs used in 
therapeutic regimes.  
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